Conditions: Metastatic Malignant Neoplasm in the Liver; Pancreatic Neuroendocrine Tumor; Stage I Pancreatic Neuroendocrine Tumor AJCC v8; Stage II Pancreatic Neuroendocrine Tumor AJCC v8; Stage III Pancreatic Neuroendocrine Tumor AJCC v8
Interventions: Drug: Capecitabine; Drug: Temozolomide
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Not yet recruiting
Feeds
6810 items (6810 unread) in 74 feeds
Acinar Cell Carcinoma
(81 unread)
Acinic Cell Carcinoma
(46 unread)
Adenoid Cystic Carcinoma
(159 unread)
Adrenal Gland Cancer
(533 unread)
Ampulla Of Vater
(68 unread)
Anal Cancer
(425 unread)
Angiosarcoma
(153 unread)
Appendix Cancer
(104 unread)
Bile Duct Cancer
(845 unread)
Brain and CNS
(878 unread)
Carcinoid
(266 unread)
Endocrine/Neuroendocrine
(808 unread)
Gall Bladder Cancer
(381 unread)
Hemangioendothelioma
(215 unread)
Hepatoblastoma
(129 unread)
Pancreas
(117 unread)
Phyllodes
(105 unread)
PMP and Mucinous Tumors
(114 unread)
Rhabdomyosarcoma
(246 unread)
Sarcoma
(1137 unread)
Trial - Neuroendocrine Cancers (72 unread)
-
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Posted: September 10th, 2021, 2:00pm GMT
-
IACS-6274 With or Without Pembrolizumab for the Treatment of Advanced Solid Tumors
Posted: September 10th, 2021, 2:00pm GMT
Conditions: Advanced Endometrial Carcinoma; Advanced Head and Neck Squamous Cell Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Melanoma; Advanced Ovarian Clear Cell Adenocarcinoma; Chondrosarcoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Refractory Endometrial Carcinoma; Refractory Head and Neck Squamous Cell Carcinoma; Refractory High Grade Ovarian Serous Adenocarcinoma; Refractory Melanoma; Refractory Ovarian Clear Cell Adenocarcinoma; Stage III Ovarian Cancer AJCC v8; Stage III Uterine Corpus Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Uterine Corpus Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Uterine Corpus Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IIIC Uterine Corpus Cancer AJCC v8; Stage IIIC1 Uterine Corpus Cancer AJCC v8; Stage IIIC2 Uterine Corpus Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8
Interventions: Drug: Glutaminase Inhibitor IPN60090; Biological: Pembrolizumab
Sponsor: M.D. Anderson Cancer Center
Recruiting -
Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 Patients
Posted: September 8th, 2021, 2:00pm GMT
Conditions: Neuroendocrine Tumor of Pancreas; Multiple Endocrine Neoplasia Type 1
Intervention: Radiation: High-dose-high precision MR-guided radiotherapy
Sponsors: J.M. de Laat; Radboud University Medical Center Nijmegen; Erasmus Medical Center; Maastricht University Medical Center; Leiden University Medical Center; University Medical Center Groningen
Not yet recruiting -
Effects of Simulated Solar Radiation on Human Skin in Preventing Skin Cancer
Posted: August 30th, 2021, 2:00pm GMT
Condition: Melanoma
Interventions: Procedure: Physical Examination; Other: Solar Simulated Light
Sponsors: OHSU Knight Cancer Institute; Oregon Health and Science University
Not yet recruiting -
A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072
Posted: August 24th, 2021, 2:00pm GMT
Condition: Neuroendocrine Tumors
Intervention: Other: Data collection
Sponsor: Ipsen
Not yet recruiting -
A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma
Posted: August 20th, 2021, 2:00pm GMT
Condition: Advanced Neuroendocrine Carcinoma
Interventions: Drug: Surufatinib plus Toripalimab; Drug: 5-fluorouracil, Calcium folinate and Irinotecan
Sponsor: Hutchison Medipharma Limited
Not yet recruiting -
Neuroendocrine Neoplasms Methylation Based Classifier - The NEMESIs-study
Posted: August 20th, 2021, 2:00pm GMT
Condition: Neuroendocrine Tumors
Intervention: Diagnostic Test: Methylation analysis
Sponsor: University Hospital, Basel, Switzerland
Not yet recruiting -
Study of 89Zr-Df-crefmirlimab PET/CT in Subjects With Advanced or Metastatic Malignancies
Posted: August 19th, 2021, 2:00pm GMT
Conditions: Melanoma; Merkel Cell Carcinoma, Unspecified; Renal Cell Carcinoma; Non Small Cell Lung Cancer
Intervention: Biological: 89Zr-Df-Crefmirlimab
Sponsors: ImaginAb, Inc.; City of Hope Medical Center
Not yet recruiting -
NTS-WBRT VS HA-WBRT in Brain Metastases
Posted: August 19th, 2021, 2:00pm GMT
Condition: Brain Metastases
Interventions: Radiation: NTS-WBRT (normal tissue sparing whole brain radiation therapy); Radiation: HA-WBRT (hippocampal avoidance whole brain radiation therapy); Drug: Memantine
Sponsor: Massachusetts General Hospital
Not yet recruiting -
Pancreatic Cancer Screening for At-risk Individuals
Posted: August 16th, 2021, 2:00pm GMT
Condition: Pancreatic Cancer, Adult
Intervention: Other: Screening for pancreatic cancer
Sponsors: Beth Israel Deaconess Medical Center; Wake Forest University Health Sciences; Washington University School of Medicine; Zucker School of Medicine at Hofstra/Northwell
Recruiting -
XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Posted: August 13th, 2021, 2:00pm GMT
Condition: Metastatic Castration-Resistant Prostate Cancer
Interventions: Combination Product: XmAb20717 + carboplatin + cabazitaxel; Combination Product: XmAb20717 + olaparib; Biological: XmAb20717 monotherapy
Sponsor: Xencor, Inc.
Not yet recruiting -
Effect of Dexmedetomidine on Quality of Recovery in Non-functioning Pituitary Adenoma Patients Undergoing Endoscopic Transsphenoidal Surgery
Posted: August 13th, 2021, 2:00pm GMT
Condition: Non-functioning Pituitary Adenoma
Interventions: Drug: Dexmedetomidine; Drug: normal saline
Sponsor: Seoul National University Hospital
Not yet recruiting -
Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors
Posted: August 12th, 2021, 2:00pm GMT
Conditions: BRAF V600E Unresectable or Metastatic Melanoma; BRAF V600E Metastatic NSCLC; Melanoma
Intervention: Drug: Encorafenib
Sponsor: Pierre Fabre Medicament
Not yet recruiting -
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Posted: August 11th, 2021, 2:00pm GMT
Conditions: Bile Duct Cancer; Gall Bladder Cancer; Breast Cancer; Neuroendocrine Tumors; Ovarian Cancer; Pancreatic Adenocarcinoma; Soft Tissue Sarcoma; Vulvar Cancer; Prostate Cancer
Interventions: Drug: Atezolizumab; Drug: Tivozanib
Sponsors: University of Florida; Genentech, Inc.; Aveo Oncology Pharmaceuticals
Not yet recruiting -
68Ga-grazytracer PET/CT in Subjects With Non-small Cell Lung Cancer or Melanoma
Posted: August 11th, 2021, 2:00pm GMT
Condition: Cancer
Intervention: Drug: 68Ga-grazytracer
Sponsors: Beijing Cancer Hospital; Peking University Health Science Center
Not yet recruiting -
Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide
Posted: August 9th, 2021, 2:00pm GMT
Condition: Meningioma
Interventions: Drug: 177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over); Drug: 177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over), Cycle 3 and 4; Drug: 177Lu-DOTA-JR11 (Phase I/II)
Sponsors: University Hospital, Basel, Switzerland; Swiss Cancer League
Recruiting -
An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors
Posted: August 6th, 2021, 2:00pm GMT
Conditions: Carcinoid Syndrome; Carcinoid Tumor; Digestive System Neuroendocrine Tumor G1; Metastatic Carcinoid Tumor
Intervention: Procedure: Dual-Energy Computed Tomography
Sponsor: M.D. Anderson Cancer Center
Recruiting -
A Study of SEA-CD40 Given With Other Drugs in Cancers
Posted: August 6th, 2021, 2:00pm GMT
Conditions: Melanoma; Carcinoma, Non-Small- Cell Lung
Interventions: Drug: SEA-CD40; Drug: pembrolizumab; Drug: pemetrexed; Drug: carboplatin
Sponsors: Seagen Inc.; Merck Sharp & Dohme Corp.
Recruiting -
Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors
Posted: August 4th, 2021, 2:00pm GMT
Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Interventions: Behavioral: Assessment; Procedure: Biospecimen Collection; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsor: M.D. Anderson Cancer Center
Recruiting -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
Posted: August 3rd, 2021, 2:00pm GMT
Conditions: Sarcoma; Melanoma
Intervention:
Sponsor: National Cancer Centre, Singapore
Recruiting -
DAY101 Monotherapy or in Combination With Other Therapies for Patients With Solid Tumors
Posted: August 2nd, 2021, 2:00pm GMT
Conditions: Melanoma; Solid Tumor
Intervention: Drug: DAY101
Sponsor: Day One Biopharmaceuticals, Inc.
Recruiting -
Optimising Molecular Radionuclide Therapy
Posted: June 11th, 2021, 2:00pm GMT
Conditions: Neuroendocrine Tumors; Hyperthyroidism; Thyroid Cancer; Thyroid Carcinoma
Interventions: Diagnostic Test: Nuclear Medicine whole-body; Diagnostic Test: SPECT/CT imaging.; Diagnostic Test: PET/CT imaging.; Device: Patient-led radiation monitor (SELFIE); Diagnostic Test: LAB TEST
Sponsors: King's College London; Guy's and St Thomas' NHS Foundation Trust
Not yet recruiting -
Study of IBI323 in Patients With Advanced Malignancies
Posted: June 7th, 2021, 2:00pm GMT
Condition: Advanced Malignancies
Intervention: Drug: IBI323
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Recruiting -
A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors
Posted: May 19th, 2021, 2:00pm GMT
Condition: Neuroendocrine Tumors
Intervention: Drug: Pelcitoclax
Sponsor: Ascentage Pharma Group Inc.
Not yet recruiting -
Expanded Access Program of Surufatinib
Posted: March 24th, 2021, 2:00pm GMT
Condition: Neuroendocrine Tumors
Intervention: Drug: Surufatinib
Sponsor: Hutchison Medipharma Limited
Available -
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers
Posted: March 17th, 2021, 2:00pm GMT
Conditions: SCLC; Small Cell Cancer; Advanced Solid Tumor; High Grade Neuroendocrine Cancers
Interventions: Drug: Lurbinectedin; Drug: Berzosertib
Sponsor: National Cancer Institute (NCI)
Recruiting -
RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors (HNSCC, Cervical) and Melanoma
Posted: February 21st, 2021, 3:00pm GMT
Conditions: Head and Neck Squamous Cell Carcinoma; Melanoma; Cervical Cancer
Intervention: Biological: RPTR-168
Sponsor: Repertoire Immune Medicines
Recruiting -
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
Posted: January 15th, 2021, 3:00pm GMT
Conditions: Gastroenteropancreatic Neuroendocrine Tumors; Pheochromocytoma; Paraganglioma
Intervention: Drug: Lutetium [177Lu] oxodotreotide/dotatate
Sponsor: Advanced Accelerator Applications
Recruiting -
A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer
Posted: January 11th, 2021, 3:00pm GMT
Condition: Neuroendocrine Prostate Cancer
Intervention: Drug: AMG 757
Sponsor: Amgen
Recruiting -
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Posted: December 14th, 2020, 3:00pm GMT
Conditions: Advanced Lung Carcinoid Tumor; Functioning Lung Carcinoid Tumor; Locally Advanced Lung Neuroendocrine Neoplasm; Lung Atypical Carcinoid Tumor; Lung Neuroendocrine Neoplasm; Lung Typical Carcinoid Tumor; Metastatic Lung Carcinoid Tumor; Metastatic Lung Neuroendocrine Neoplasm; Non-Functioning Lung Carcinoid Tumor; Recurrent Lung Neuroendocrine Neoplasm; Unresectable Lung Carcinoid Tumor; Unresectable Lung Neuroendocrine Neoplasm
Interventions: Drug: Everolimus; Drug: Lutetium Lu 177 Dotatate
Sponsor: National Cancer Institute (NCI)
Not yet recruiting -
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Posted: October 8th, 2020, 2:00pm GMT
Conditions: Metastatic Solid Tumor; Colorectal Cancer; Neuroendocrine Tumors; Small Cell Lung Cancer; Gastric Cancer; Soft Tissue Sarcoma
Interventions: Drug: Surufatinib and Tislelizumab _ Part 1; Drug: Surufatinib and Tislelizumab _ Part 2
Sponsors: Hutchison Medipharma Limited; BeiGene
Recruiting -
Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
Posted: September 4th, 2020, 2:00pm GMT
Conditions: EGFR-Mutated Non-Small-Cell Lung Carcinoma; Small Cell/Neuroendocrine
Interventions: Drug: Olaparib; Drug: Durvalumab
Sponsor: National Cancer Institute (NCI)
Recruiting -
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
Posted: August 24th, 2020, 2:00pm GMT
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Intervention: Drug: arginine/lysine
Sponsor: Advanced Accelerator Applications
Recruiting -
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
Posted: August 17th, 2020, 2:00pm GMT
Conditions: Metastatic Lung Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Neuroendocrine Carcinoma; Metastatic Pancreatic Adenocarcinoma; Stage III Lung Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Unresectable Lung Small Cell Carcinoma; Unresectable Malignant Solid Neoplasm; Unresectable Neuroendocrine Carcinoma; Unresectable Pancreatic Adenocarcinoma
Interventions: Drug: Elimusertib; Drug: Irinotecan Hydrochloride; Drug: Topotecan Hydrochloride
Sponsor: National Cancer Institute (NCI)
Recruiting -
Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s
Posted: July 27th, 2020, 2:00pm GMT
Conditions: Neuroendocrine Tumors; Carcinoma, Neuroendocrine
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting -
Prospective Evaluation of a Program for Early Identification of Needs and Multidisciplinary Intervention in Supportive Care in Digestive Oncology
Posted: July 20th, 2020, 2:00pm GMT
Conditions: Non-colorectal Cancer (Esophagus, Stomach, Liver/Bile Ducts, Pancreas, Neuroendocrine Carcinoma); Colorectal With Associated Risk Factors
Intervention: Other: multidisciplinary assessment and intervention
Sponsor: Institut Curie
Recruiting -
A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for Delta-Like Ligand 3 (DLL3).
Posted: June 12th, 2020, 2:00pm GMT
Condition: Patients With Small Cell Lung Carcinoma and Other Neoplasms
Intervention: Drug: BI 764532
Sponsor: Boehringer Ingelheim
Recruiting -
A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET
Posted: June 11th, 2020, 2:00pm GMT
Conditions: Metastatic Well Differentiated Neuroendocrine Neoplasm; Neuroendocrine Tumors
Interventions: Drug: Cabozantinib; Drug: Lanreotide
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Recruiting -
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
Posted: May 20th, 2020, 2:00pm GMT
Conditions: Advanced Adrenal Gland Pheochromocytoma; Advanced Paraganglioma; Metastatic Adrenal Gland Pheochromocytoma; Metastatic Paraganglioma; Unresectable Adrenal Gland Pheochromocytoma; Unresectable Paraganglioma
Interventions: Drug: Olaparib; Other: Quality-of-Life Assessment; Drug: Temozolomide
Sponsor: National Cancer Institute (NCI)
Recruiting -
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
Posted: May 15th, 2020, 2:00pm GMT
Condition: Advanced Cancer
Intervention: Combination Product: X-PACT
Sponsor: Immunolight, LLC
Not yet recruiting -
Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET
Posted: May 13th, 2020, 2:00pm GMT
Condition: Neuroendocrine Tumors
Intervention: Drug: 177Lu-Dotatate
Sponsor: IRCCS San Raffaele
Recruiting -
National Cancer Institute "Cancer Moonshot Biobank"
Posted: March 19th, 2020, 2:00pm GMT
Conditions: Castration-Resistant Prostate Carcinoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Hematopoietic and Lymphoid Cell Neoplasm; Lung Non-Small Cell Carcinoma; Lung Small Cell Carcinoma; Malignant Solid Neoplasm; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Refractory Plasma Cell Myeloma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8
Interventions: Procedure: Biospecimen Collection; Other: Medical Chart Review
Sponsor: National Cancer Institute (NCI)
Recruiting -
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
Posted: February 26th, 2020, 3:00pm GMT
Conditions: Recurrent Adrenal Gland Pheochromocytoma; Recurrent Ectomesenchymoma; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Kidney Wilms Tumor; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Medulloblastoma; Recurrent Melanoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Recurrent Rhabdoid Tumor of the Kidney; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent Thyroid Gland Carcinoma; Recurrent WHO Grade II Glioma; Refractory Adrenal Gland Pheochromocytoma; Refractory Ependymoma; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Medulloblastoma; Refractory Melanoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Rhabdoid Tumor of the Kidney; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Refractory Thyroid Gland Carcinoma; Refractory WHO Grade II Glioma
Intervention: Drug: Tipifarnib
Sponsor: National Cancer Institute (NCI)
Recruiting -
Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients
Posted: January 29th, 2020, 3:00pm GMT
Conditions: Breast Cancer; Gastric Cancer; Chordoma; Lung Cancer; Ovarian Cancer; Prostate Cancer; Colorectal Cancer; Pancreatic Cancer; Hepatocellular Cancer; Merkel Cell Carcinoma; Small-cell Lung Cancer
Intervention: Biological: TAEK-VAC-HerBy
Sponsor: Bavarian Nordic
Recruiting -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Posted: January 27th, 2020, 3:00pm GMT
Conditions: Advanced Solid Tumor; MSI-H/dMMR Tumors; Cutaneous Squamous Cell Carcinoma; Urothelial Carcinoma; Cervical Cancer; HepatoCellular Carcinoma; Esophageal Squamous Cell Carcinoma; Merkel Cell Carcinoma; Small-cell Lung Cancer; Mesothelioma; PD-L1 Amplified Tumor (9p24.1); Nasopharyngeal Carcinoma
Intervention: Drug: INCB099280
Sponsor: Incyte Corporation
Recruiting -
Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors
Posted: January 21st, 2020, 3:00pm GMT
Conditions: Digestive System Neuroendocrine Tumor; Metastatic Well Differentiated Neuroendocrine Neoplasm
Interventions: Drug: Lutetium Lu 177 Dotatate; Drug: Triapine
Sponsor: National Cancer Institute (NCI)
Recruiting -
Detection of PitNET Tissue During TSS Using Bevacizumab-800CW
Posted: December 30th, 2019, 3:00pm GMT
Conditions: Pituitary Tumor; Pituitary Adenoma; Pituitary Macroadenoma
Interventions: Drug: Bevacizumab-IRDye800CW; Device: Molecular Fluorescence Endoscopy platform
Sponsor: University Medical Center Groningen
Recruiting -
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Posted: December 26th, 2019, 3:00pm GMT
Condition: Medullary Thyroid Cancer
Interventions: Drug: Selpercatinib; Drug: Cabozantinib; Drug: Vandetanib
Sponsors: Loxo Oncology, Inc.; Eli Lilly and Company
Recruiting -
Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Posted: September 18th, 2019, 2:00pm GMT
Conditions: HLA-A2 Positive Cells Present; Refractory Melanoma
Interventions: Biological: Alpha-type-1 Polarized Dendritic Cells; Drug: Celecoxib; Drug: PD-1 Ligand Inhibitor; Drug: PD1 Inhibitor; Biological: Recombinant Interferon Alfa-2b; Drug: Rintatolimod
Sponsors: Roswell Park Cancer Institute; National Cancer Institute (NCI)
Not yet recruiting -
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Posted: September 11th, 2019, 2:00pm GMT
Conditions: Gastroenteropancreatico Tumors; Neuroendocrine Tumors; Neuroendocrine Neoplasms
Interventions: Drug: Lu-177-DOTATATE; Drug: Olaparib; Diagnostic Test: Ga dotatate scanning; Diagnostic Test: FDG-PET scanning
Sponsor: National Cancer Institute (NCI)
Not yet recruiting -
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
Posted: September 6th, 2019, 2:00pm GMT
Conditions: Metastatic Large Cell Neuroendocrine Carcinoma; Metastatic Neuroendocrine Carcinoma; Metastatic Neuroendocrine Neoplasm; Metastatic Small Cell Neuroendocrine Carcinoma
Interventions: Drug: Cabozantinib S-malate; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting -
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Posted: August 29th, 2019, 2:00pm GMT
Conditions: VHL Pancreatic Neuroendocrine Tumors; Von Hippel-Lindau Disease; Neuroendocrine Tumors
Intervention: Drug: 68-Gallium DOTATATE
Sponsor: National Cancer Institute (NCI)
Recruiting -
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study
Posted: August 28th, 2019, 2:00pm GMT
Conditions: Advanced Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma; Collecting Duct Carcinoma; Kidney Medullary Carcinoma; Metastatic Malignant Neoplasm in the Bone; Papillary Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8; Unclassified Renal Cell Carcinoma
Interventions: Drug: Cabozantinib S-malate; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Radium Ra 223 Dichloride
Sponsor: National Cancer Institute (NCI)
Recruiting -
Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs
Posted: April 1st, 2019, 2:00pm GMT
Conditions: Bladder Small Cell Neuroendocrine Carcinoma; Extensive Stage Lung Small Cell Carcinoma; Extrapulmonary Small Cell Neuroendocrine Carcinoma; Limited Stage Lung Small Cell Carcinoma; Platinum-Resistant Lung Small Cell Carcinoma; Platinum-Sensitive Lung Small Cell Carcinoma; Prostate Small Cell Neuroendocrine Carcinoma; Recurrent Lung Small Cell Carcinoma
Interventions: Drug: Berzosertib; Drug: Topotecan Hydrochloride
Sponsor: National Cancer Institute (NCI)
Recruiting -
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Posted: March 7th, 2019, 3:00pm GMT
Conditions: Bladder Adenocarcinoma; Bladder Clear Cell Adenocarcinoma; Bladder Mixed Adenocarcinoma; Bladder Neuroendocrine Carcinoma; Bladder Small Cell Neuroendocrine Carcinoma; Bladder Squamous Cell Carcinoma; Bladder Urachal Adenocarcinoma; Chromophobe Renal Cell Carcinoma; Collecting Duct Carcinoma; Infiltrating Bladder Lymphoepithelioma-Like Carcinoma; Infiltrating Bladder Urothelial Carcinoma; Infiltrating Bladder Urothelial Carcinoma With Giant Cells; Infiltrating Bladder Urothelial Carcinoma, Nested Variant; Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant; Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant; Kidney Medullary Carcinoma; Large Cell Neuroendocrine Carcinoma; Metastatic Bladder Carcinoma; Metastatic Bladder Large Cell Neuroendocrine Carcinoma; Metastatic Bladder Small Cell Neuroendocrine Carcinoma; Metastatic Bladder Squamous Cell Carcinoma; Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant; Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant; Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant; Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant; Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant; Metastatic Kidney Medullary Carcinoma; Metastatic Malignant Genitourinary System Neoplasm; Metastatic Penile Carcinoma; Metastatic Prostate Small Cell Neuroendocrine Carcinoma; Metastatic Sarcomatoid Renal Cell Carcinoma; Metastatic Urethral Carcinoma; Papillary Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage IV Bladder Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8; Stage IVA Bladder Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Bladder Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Testicular Leydig Cell Tumor; Testicular Sertoli Cell Tumor; Urethral Clear Cell Adenocarcinoma
Interventions: Drug: Cabozantinib S-malate; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting -
Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer, STAMP Study
Posted: October 19th, 2018, 2:00pm GMT
Conditions: Pathologic Stage I Merkel Cell Carcinoma AJCC v8; Pathologic Stage II Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8; Pathologic Stage III Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
Interventions: Other: Best Practice; Biological: Pembrolizumab; Radiation: Radiation Therapy
Sponsor: National Cancer Institute (NCI)
Recruiting -
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
Posted: June 1st, 2018, 2:00pm GMT
Conditions: Melanoma (Skin); Skin Cancer; Skin Melanoma; Skin Carcinoma
Interventions: Drug: Vemurafenib; Drug: Cobimetinib
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting -
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
Posted: April 20th, 2018, 2:00pm GMT
Conditions: Non Small Cell Lung Cancer; Triple Negative Breast Cancer; Melanoma; Head and Neck Cancer
Interventions: Biological: CAB-ROR2-ADC; Biological: PD-1 inhibitor
Sponsor: BioAtla, Inc.
Recruiting -
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Posted: December 18th, 2017, 3:00pm GMT
Conditions: Atypical Carcinoid Tumor; Carcinoid Tumor; Functioning Pancreatic Neuroendocrine Tumor; Intermediate Grade Lung Neuroendocrine Neoplasm; Locally Advanced Pancreatic Neuroendocrine Tumor; Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm; Low Grade Lung Neuroendocrine Neoplasm; Lung Atypical Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Neoplasm; Metastatic Digestive System Neuroendocrine Tumor G1; Metastatic Pancreatic Neuroendocrine Tumor; Metastatic Thymic Neuroendocrine Neoplasm; Neuroendocrine Neoplasm; Non-Functioning Pancreatic Neuroendocrine Tumor; Pancreatic Serotonin-Producing Neuroendocrine Tumor; Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7; Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7; Stage IV Digestive System Neuroendocrine Tumor AJCC v7
Interventions: Drug: Cabozantinib S-malate; Other: Laboratory Biomarker Analysis; Other: Placebo Administration; Other: Quality-of-Life Assessment
Sponsor: National Cancer Institute (NCI)
Recruiting -
Phase Ib of L-NMMA and Pembrolizumab
Posted: August 2nd, 2017, 2:00pm GMT
Conditions: Non-Small Cell Lung Cancer; Malignant Melanoma; Head and Neck Squamous Cell Carcinoma; Classical Hodgkin Lymphoma; Urothelial Carcinoma Bladder; DNA Repair-Deficiency Disorders
Interventions: Drug: L-NMMA; Drug: Pembrolizumab
Sponsor: The Methodist Hospital Research Institute
Recruiting -
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Posted: July 2nd, 2017, 2:00pm GMT
Conditions: Pheochromocytoma; Paraganglioma; Neuroendocrine Tumors; Neuroendocrine Neoplasms
Interventions: Drug: Lu-177-DOTATATE; Drug: Ga-68-DOTATATE; Drug: F-18-FDG; Drug: Amino Acid solution
Sponsor: National Cancer Institute (NCI)
Recruiting -
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
Posted: February 9th, 2017, 3:00pm GMT
Condition: Neuroendocrine Tumors
Interventions: Drug: 177Lu-edotreotide PRRT; Drug: Everolimus; Other: Amino-Acid Solution
Sponsors: ITM Solucin GmbH; ABX CRO; PSI CRO
Recruiting -
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
Posted: January 31st, 2017, 3:00pm GMT
Conditions: RET-altered Non Small Cell Lung Cancer; Medullary Thyroid Cancer; RET-altered Papillary Thyroid Cancer; RET-altered Colon Cancer; RET-altered Solid Tumors; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Thyroid Diseases; Thyroid Neoplasm; Thyroid Cancer, Papillary; Carcinoma, Neuroendocrine; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Neoplasms; Endocrine System Diseases; Endocrine Gland Neoplasm; Head and Neck Neoplasms; Adenocarcinoma, Papillary; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Colonic Neoplasms; Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasm; Digestive System Disease; Gastrointestinal Disease; Colonic Diseases; Intestinal Disease
Intervention: Drug: pralsetinib (BLU-667)
Sponsor: Hoffmann-La Roche
Recruiting -
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Posted: December 1st, 2016, 3:00pm GMT
Conditions: Adenoid Cystic Skin Carcinoma; Adnexal Carcinoma; Anaplastic Large Cell Lymphoma, ALK-Negative; Anaplastic Large Cell Lymphoma, ALK-Positive; Apocrine Carcinoma; Cylindrocarcinoma; Digital Papillary Adenocarcinoma; Endocrine Mucin-Producing Sweat Gland Carcinoma; Extramammary Paget Disease; Extraocular Cutaneous Sebaceous Carcinoma; Hidradenocarcinoma; Keratoacanthoma; Malignant Sweat Gland Neoplasm; Merkel Cell Carcinoma; Microcystic Adnexal Carcinoma; NK-Cell Lymphoma, Unclassifiable; Papillary Adenocarcinoma; Porocarcinoma; Primary Cutaneous Mucinous Carcinoma; Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent T-Cell Non-Hodgkin Lymphoma; Refractory Anaplastic Large Cell Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Refractory Merkel Cell Carcinoma; Refractory Mycosis Fungoides; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Skin Squamous Cell Carcinoma; Refractory T-Cell Non-Hodgkin Lymphoma; Sezary Syndrome; Signet Ring Cell Carcinoma; Skin Basal Cell Carcinoma; Skin Basosquamous Cell Carcinoma; Skin Squamous Cell Carcinoma; Spiradenocarcinoma; Squamoid Eccrine Ductal Carcinoma; Squamous Cell Carcinoma of Unknown Primary; Sweat Gland Carcinoma; Trichilemmal Carcinoma; Vulvar Squamous Cell Carcinoma
Interventions: Other: Laboratory Biomarker Analysis; Biological: Nivolumab; Biological: Talimogene Laherparepvec
Sponsor: National Cancer Institute (NCI)
Recruiting -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Posted: July 15th, 2016, 2:00pm GMT
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Breast Metaplastic Carcinoma; Cervical Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Solid Neoplasm; Malignant Testicular Sex Cord-Stromal Tumor; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting -
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer
Posted: February 12th, 2016, 3:00pm GMT
Conditions: Melanoma; Non-small Cell Lung Cancer; Brain Metastasis
Intervention: Drug: Pembrolizumab plus Bevacizumab
Sponsor: Yale University
Recruiting -
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Posted: October 5th, 2015, 2:00pm GMT
Conditions: Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, Anaplastic; Melanoma; Neuroendocrine Tumors; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Primary Brain Tumors; Renal Cell Carcinoma; Sarcomas; Salivary Gland Cancers; Adult Solid Tumor
Intervention: Drug: Entrectinib
Sponsor: Hoffmann-La Roche
Recruiting -
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Posted: June 8th, 2015, 2:00pm GMT
Conditions: Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Kidney Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Neoplasm; Melanoma; Ovarian Carcinoma; Pancreatic Carcinoma; Plasma Cell Myeloma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Ovarian Carcinoma; Recurrent Pancreatic Carcinoma; Recurrent Plasma Cell Myeloma; Recurrent Prostate Carcinoma; Recurrent Rectal Carcinoma; Recurrent Skin Carcinoma; Recurrent Thyroid Gland Carcinoma; Recurrent Uterine Corpus Cancer; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Plasma Cell Myeloma; Skin Carcinoma; Thyroid Gland Carcinoma; Uterine Corpus Cancer
Interventions: Drug: Adavosertib; Drug: Afatinib; Drug: Afatinib Dimaleate; Drug: Binimetinib; Drug: Capivasertib; Drug: Copanlisib; Drug: Copanlisib Hydrochloride; Drug: Crizotinib; Other: Cytology Specimen Collection Procedure; Drug: Dabrafenib; Drug: Dabrafenib Mesylate; Drug: Dasatinib; Drug: Defactinib; Drug: Defactinib Hydrochloride; Drug: Erdafitinib; Drug: FGFR Inhibitor AZD4547; Drug: Ipatasertib; Other: Laboratory Biomarker Analysis; Drug: Larotrectinib; Drug: Larotrectinib Sulfate; Biological: Nivolumab; Drug: Osimertinib; Drug: Palbociclib; Biological: Pertuzumab; Drug: PI3K-beta Inhibitor GSK2636771; Biological: Relatlimab; Drug: Sapanisertib; Drug: Sunitinib Malate; Drug: Taselisib; Drug: Trametinib; Biological: Trastuzumab; Biological: Trastuzumab Emtansine; Drug: Ulixertinib; Drug: Vismodegib
Sponsor: National Cancer Institute (NCI)
Recruiting -
The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
Posted: November 4th, 2014, 3:00pm GMT
Condition: Pancreatic Neuroendocrine Tumors
Intervention: Drug: sunitinib
Sponsor: Pfizer
Recruiting -
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
Posted: May 23rd, 2014, 2:00pm GMT
Conditions: Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Extrapulmonary Small Cell Cancer; Pulmonary Neuroendocrine Tumors; Thymic Epithelial Tumors
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting -
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
Posted: December 25th, 2013, 3:00pm GMT
Conditions: Cervical Adenocarcinoma; Cervical Adenosarcoma; Cervical Adenosquamous Carcinoma; Cervical Carcinosarcoma; Cervical Squamous Cell Carcinoma, Not Otherwise Specified; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Mucinous Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Fallopian Tube Adenocarcinoma; Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Squamous Cell Carcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; High Grade Ovarian Serous Adenocarcinoma; Malignant Female Reproductive System Neoplasm; Malignant Ovarian Clear Cell Tumor; Malignant Ovarian Endometrioid Tumor; Malignant Ovarian Epithelial Tumor; Malignant Ovarian Mucinous Tumor; Malignant Peritoneal Neoplasm; Malignant Solid Neoplasm; Ovarian Carcinosarcoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Platinum-Sensitive Ovarian Carcinoma; Primary Peritoneal Carcinosarcoma; Primary Peritoneal Clear Cell Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Primary Peritoneal Transitional Cell Carcinoma; Primary Peritoneal Undifferentiated Carcinoma; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma; Uterine Corpus Carcinosarcoma
Interventions: Biological: Bevacizumab; Other: Laboratory Biomarker Analysis; Drug: Nab-paclitaxel; Other: Pharmacological Study
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting -
Dabrafenib, Trametinib, and Navitoclax in Treating Patients With BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Posted: November 21st, 2013, 3:00pm GMT
Conditions: Malignant Solid Neoplasm; Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma
Interventions: Drug: Dabrafenib; Other: Laboratory Biomarker Analysis; Biological: Navitoclax; Other: Pharmacological Study; Drug: Trametinib
Sponsor: National Cancer Institute (NCI)
Recruiting